Safety of Lorlatinib in Patients with Unresectable Advanced <i>ALK</i>-Positive Non-Small-Cell Lung Cancer Previously Treated with ALK Inhibitors: A Single-Arm, Open-Label, Phase IV Study in India

Lorlatinib is approved in India for patients with previously treated anaplastic lymphoma kinase (ALK)–positive advanced or recurrent non-small-cell lung cancer (NSCLC). Owing to the limited number of Indian patients in phase I/II and III studies, a postapproval study was conducted to report the safe...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Ullas Batra, Vineet G. Gupta, Nirmal Raut, Tushar Patil, Harsha Panchal, Nikhil Ghadyalpatil, Anand Pathak, Chirag Desai, Shailesh Bondarde, Minish Jain, Christian Russel Reyes, Shyam Parvatini, Seema Pai, Francesca Toffalorio, Holger Thurm, Bivas Biswas
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2025-08-01
Saila:	Indian Journal of Medical and Paediatric Oncology
Gaiak:	ALK tyrosine kinase inhibitor lorlatinib non-small-cell lung cancer safety
Sarrera elektronikoa:	http://www.thieme-connect.de/DOI/DOI?10.1055/s-0045-1801883
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!